Eir Ventures Danmark ApS

The purpose of the company is to conduct fund management advisory for Eir Ventures Partners AB and Eir Ventures I AB. Eir Ventures AB I have a total committed capital of € 122,4 million from leading Nordic and European fund-of-fund investors as well as family offices, private individuals and Nordic Universities. During 2024, Eir Ventures completed as follow on financings in several portfolio companies and seen positive developments in a majority of our companies. By the end of 2025 we have maintained the 17 active companies in the portfolio that we entered the year with. Several companies reported achievement of significant milestones, such as initiation of clinical studies, data read out from ongoing studies as well as other significant development progress or corporate development.

Financial review

The company's income statement for the year ended 31 December 2025 shows a profit of EUR 526, and the balance sheet at 31 December 2025 shows negative equity of EUR 1.802.

2025 has continues to be a year dominated by uncertainties and headwinds for the sector. Allocations to the life science sector among institutional investors have generally decreased, and the continuous geopolitical uncertainty negatively affect investment and risk appetite. We continue to see financings taking longer to conclude. More than ever, a specialized life science investor has abundant opportunities as well as an essential role in the Nordic life science ecosystem. Eir Ventures Danmark ApS is not directly affected by the challenging general conditions, as the activities and financial outlook of the company is vested in the advisory agreement with Eir Ventures Partners AB and Eir Ventures I AB.

Recognition and measurement uncertaintiesThe recognition and measurement of items in the annual report is not associated with any uncertainty.

The company's financial position at 31 December 2025 and the results of its operations for the financial year ended 31 December 2025 are not affected by any unusual matters.

No events have occurred after the balance sheet date which could significantly affect the company's financial position.